This page has been robot translated, sorry for typos if any. Original content here.

Attention! Information is for reference only!
Before taking, be sure to consult a doctor!
SITE ONLY DIRECTORY. NOT A PHARMACY! We do not sell medicines! None!

Antihyperlipoproteinemic (anti-atherosclerotic) agents

By hyperlipoproteinemia imply conditions in which
blood plasma has a high content of lipoproteins that carry cholesterol.
rin and triglycerides. According to generally accepted ideas,
the content of these lipoproteins contributes to the development of atherosclerosis.
Recently, the question of the role of cholesterol in the pathogenesis of athero-
sclerosis is debatable. However, perennial
clinical observations suggest that increasing concentration
lipoproteins increases the risk of atherosclerosis and, as an example,
the use of hypolipidemic drugs
action, leads to a prophylactic and therapeutic effect with
treatment of atherosclerosis-related cardiovascular diseases.
There are several types of lipoproteins involved in the transfer
cholesterol and phospholipids. The main ones are Khilomicrons,
transporting mainly exogenous triglycerides: K lipoprotein
Very low density (VLDL) yoins that carry mostly endogenous
triglycerides; low density lipoproteins (LDL) transporting,
as a rule, cholesterol (cholesterol esters); K high lipoproteins
density (HDL), which carry cholesterol in the first place, as well as
same phospholipids.
Different lipoproteins play an unequal role in the development of athero-
sclerosis. VLDL transmits endogenous triglycerides and cholesterol to
peripheral tissue. LDLP forms LDL transmitting
cholesterol peripheral tissues, including the blood circulation
vessels that may contribute to the development of atherosclerosis or
deepening the process that has already begun. Thus, VLDL and LDL
are considered as K atherogenic lipoproteins. PAPs mobilize
cholesterol from tissues, including from the walls of blood vessels, and considered
Kantiatogennye lipoproteins.
Despite controversial questions about the role of cholesterol in the pathogenesis
atherosclerosis, hypolipidemic agents continue to apply;
In addition, new lipid-lowering drugs are being sought.
Optimal are drugs that reduce the level of LDL and one
temporarily increasing the concentration of HDL.
Synthesis of lipoproteins and cholesterol metabolism are complex
biological processes, therefore, influence them in that
or a different degree may be substances related to different pharmacological
groups, including drugs that regulate the functions of the central nervous system
(hypnotics, tranquilizers, etc.) and metabolic processes (lipotropic
drugs, hormonal drugs.). Apply for this purpose also
some herbal drugs and others. Some
Kparmidin has anti-sclerotic effect (see).
An effective hypocholesterolemic agent is K acid.
nicotine (cm).
Limited use as lipid-lowering drugs,
have drugs of unsaturated fatty acids (see Linetol, Lipostabil).
[Previously used as a hypolipidemic drug
Cettamiphene is excluded from the range of drugs as low
effective. The preparation Karahiden is also excluded.].
The main modern antihyperlipoproteinemic (hypocholeste)
rinemic) drugs are divided into two groups: a) drugs,
inhibiting mainly cholesterol absorption from the intestines
(cholestyramine, etc.); b) drugs that inhibit biosynthesis and transfer
cholesterol and triglycerides (fibrates, probucol, etc.).
As a rule, lipid-lowering drugs are used in complex
treatment of diseases associated with or due to impaired
lipid metabolism (especially diseases of the cardiovascular system).
The choice of drug is determined by the type of hyperlipoproteinemia, clinical
picture of the disease, efficacy and tolerability of the drug.
Prerequisites for the success of pharmacotherapy are compliance
diet, elimination of predisposing factors (smoking, violation
diets, etc.).

Subgroup Antihyperlipoproteinemic (anti-atherosclerotic) agents include drugs: